Who Paid My Doc
Shivinder Deol
Family Medicine Bakersfield, CA Medical Doctor
NPI 1558447250 CMS profile 407404
4000 Stockdale Hwy, Ste D, Bakersfield, CA 93309
General payments
$482
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Shivinder Deol of Bakersfield, CA is reported in the CMS Open Payments database as having received $482 across 13 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 58th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $55 | 3 | |
| 2024 | General | $78 | 4 | |
| 2023 | General | $55 | 3 | |
| 2022 | General | $125 | 1 | |
| 2020 | General | $35 | 1 | |
| 2019 | General | $135 | 1 |
Beside peers
- Shivinder Deol
- Family Medicine median
- Middle half of Family Medicine
- National median
In program year 2025, general payments to Shivinder Deol were reported at $55. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.
Show as a table
| Year | Shivinder Deol | Family Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $135 | $150 | $41–$543 | $163 |
| 2020 | $35 | $120 | $32–$415 | $114 |
| 2021 | $0 | $137 | $35–$551 | $132 |
| 2022 | $125 | $137 | $37–$512 | $149 |
| 2023 | $55 | $149 | $42–$545 | $160 |
| 2024 | $78 | $156 | $44–$560 | $164 |
| 2025 | $55 | $155 | $45–$549 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 107 drugsPart D claims
6,110
Drug cost
$278,413
Branded share of claims
24.5%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ozempic Semaglutide | Brand | 42 | $42,353 | |
| Rybelsus Semaglutide | Brand | 32 | $41,745 | |
| Januvia Sitagliptin Phosphate | Brand | 46 | $35,801 | |
| Jardiance Empagliflozin | Brand | 17 | $17,672 | |
| Calcitonin-Salmon Calcitonin,salmon,synthetic | Brand | 226 | $17,614 | |
| Tradjenta Linagliptin | Brand | 16 | $16,188 | |
| Liothyronine Sodium | Generic | 315 | $14,120 | |
| Eliquis Apixaban | Brand | 16 | $11,127 | |
| Linzess Linaclotide | Brand | 11 | $8,997 | |
| Breo Ellipta Fluticasone/Vilanterol | Brand | 11 | $5,004 |
The 10 drugs with the highest cost, of 107 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 77 billing codesPaid by Medicare
$202,238
Medicare patients
385
Services billed
46,737
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 66% | |
| Arthritis | 39% | |
| Ischemic heart disease | 25% | |
| Diabetes | 23% | |
| Osteoporosis | 17% | |
| Depression | 14% | |
| Chronic kidney disease | 13% | |
| COPD | 11% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, pyridoxine hcl, 100 mg J3415 | Office | 179 | 707 | $7,330 |
| Injection, estradiol valerate, up to 10 mg J1380 | Office | 104 | 819 | $4,956 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 | Office | 223 | 1,237 | $1,156 |
| Injection, testosterone cypionate, 1 mg J1071 | Office | 25 | 37,010 | $699 |
| Injection, progesterone, per 50 mg J2675 | Office | 107 | 815 | $452 |
| Injection, ceftriaxone sodium, per 250 mg J0696 | Office | 64 | 416 | $139 |
| Injection, magnesium sulfate, per 500 mg J3475 | Office | 36 | 94 | $42 |
| 5% dextrose/normal saline (500 ml = 1 unit) J7042 | Office | 24 | 35 | $34 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
13 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Family Medicine in California
Related records
Family Medicine in California
Practitioners in the same specialty and state, ranked by reported value.
All Family Medicine
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.